SecBot SecBot
PRESS-RELEASE ·Filed May 7, 2026

TRDA

Entrada Therapeutics, Inc.
MIXED
Impact 6/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The positive ENTR-601-44 data is a major catalyst but the sharp revenue decline and widening loss cap upside. Watch for upcoming ELEVATE-45-201 data in mid-2026 and further cohort readouts by year-end to validate the platform.

DirectionMixed
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.85
T+0 close · May 7, 2026 · via day close
Latest settled
+5.99%
T+60 · $7.26
Vs SPY
+2.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $6.85entry
  2. T+1 · 6mo ago −0.15%α −0.98% · $6.84
  3. T+5 · 6mo ago +6.86%α +5.36% · $7.32
  4. T+20 · 6mo ago −3.94%α −7.08% · $6.58
  5. T+60 · 4mo ago +5.99%α +2.15% · $7.26
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Entrada Therapeutics reported Q1 2026 results with a net loss of $39.7M ($0.95/share), beating consensus EPS of -$1.06 by 10.4%. Collaboration revenue plunged to $0.9M from $20.6M a year ago as the Vertex research plan completed, but the company highlighted positive clinical data from ENTR-601-44 in Duchenne muscular dystrophy, showing favorable safety and early functional benefit.

Key Financial Metrics

EPS
−$0.95
est −$1.06 · +10.4%
Revenue
$875.0K
-95.7% YoY
Rating
beat

Key Facts

  • Net loss widened to $39.7M in Q1 2026 from $17.3M in Q1 2025 due to higher R&D costs and lower collaboration revenue.
  • Collaboration revenue declined to $0.9M from $20.6M YoY as the Vertex VX-670 research plan substantially completed.
  • Positive topline results from ELEVATE-44-201 Cohort 1: favorable safety, statistically significant improvement in Time to Rise velocity.
  • Cash, cash equivalents and marketable securities of $254.9M, expected to fund operations into Q3 2027.
  • EPS of -$0.95 beat the -$1.06 consensus by 10.4%.

Financial Impact

Net loss increased 129% YoY to $39.7M; revenue decreased 96% to $0.9M.

revenuenet losscash

Risk Factors

  • Clinical development risk for DMD programs; reliance on positive data from ongoing and future cohorts.
  • Dependence on Vertex partnership for VX-670; any setbacks could impact investor sentiment.
  • Cash burn rate; runway only into Q3 2027 without additional financing or partnership milestones.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3289842

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026